& North Area Prescribing Committee (APC)

Policy Statement Domperidone for treating gastroparesis in adults

APC 481-2020 Policy No: February 2020 Date of Issue February 2023 No review date will be assigned to any drugs or devices Review Date: that are subject to a NICE Technology appraisal. The recommendation made by the APC will be reviewed when new published evidence becomes available OR there is new published national guidance e.g. NICE) Recommendations: The Area Prescribing Committee recommends the use of domperidone for the treatment of gastroparesis in adults only when prescribed within a secondary care setting.

Domperidone will be considered RED on the traffic light system for this indication.

Prescribers should ensure that the patient understands the risks and consents to using domperidone off-label noting the MHRA alert (updated 2019)

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication

Key Considerations:  MHRA Drug Safety Update, December 2019: https://www.gov.uk/drug-safety- update/domperidone-for-nausea-and-vomiting-lack-of-efficacy-in-children- reminder-of-contraindications-in-adults-and-adolescents

 Numbers are expected to be small and risk of long term use.

Date taken to Area Prescribing Committee 5th February 2020

Agreed by APC 13th February 2020 members

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & CCG), CCG and Horsham & Mid- Sussex CCG